Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Past prior SM interpreted as negative or benign \[Breast Imaging Reporting and Data System (BI-RADS) Category 1 or 2\]~* Past prior SM interpreted as heterogeneously dense or extremely dense~Exclusion Criteria:~* Subject is unable to understand and sign the consent form~* Subject is pregnant or lactating~* Subject is physically unable to sit upright and still for 40 minutes~* Subject has self-reported signs or symptoms of breast cancer (palpable mass, bloody nipple discharge, axillary mass, etc.)~* Subject has had needle biopsy within 3 months, or breast surgery within 1 year prior to the study~* Subject is currently taking tamoxifen, Evista (raloxifene), Zoladex or an aromatase inhibitor for adjuvant therapy or chemoprevention.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mammography and Molecular Breast Imaging (Type: EXPERIMENTAL): Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (8-mCi) Technetium (99mTc) sestamibi injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).